Phosphorylation of human estrogen receptor-beta at serine 105 inhibits breast cancer cell migration and invasion

Molecular and Cellular Endocrinology

Volumn 358, Issue 1, 2012, Pages 27-35

  Lam, Hung Ming ^a   Suresh Babu, C V ^a   Wang, Jiang ^a   Yuan, Yong ^a   Lam, Ying Wai ^a   Ho, Shuk Mei ^a,b   Leung, Yuet Kin ^a,c  

^a UNIVERSITY OF CINCINNATI MEDICAL CENTER   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

Breast cancer; Estrogen receptor beta isoforms; Invasion; Migration; Phospho mimetics; Phosphorylation

Indexed keywords

ESTROGEN RECEPTOR BETA; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE P38; SERINE; SERINE 105; SERINE 75; SERINE 87; UNCLASSIFIED DRUG;

AMINO TERMINAL SEQUENCE; ARTICLE; BREAST CANCER; CANCER CELL; CELL CYCLE PROGRESSION; CELL GROWTH; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MASS SPECTROMETRY; PREVALENCE; PRIORITY JOURNAL; PROTEIN MODIFICATION; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION; SITE DIRECTED MUTAGENESIS; TRANSACTIVATION;

ANTIBODIES; BREAST NEOPLASMS; CELL CYCLE; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; ESTROGEN RECEPTOR BETA; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FEMALE; HEK293 CELLS; HUMANS; MAP KINASE SIGNALING SYSTEM; NEOPLASM INVASIVENESS; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHORYLATION; PROTEIN PROCESSING, POST-TRANSLATIONAL; TRANSCRIPTIONAL ACTIVATION;

EID: 84862777435     PISSN: 03037207     EISSN: 18728057     Source Type: Journal    
DOI: 10.1016/j.mce.2012.02.012     Document Type: Article

References (51)

1. Allred D.C., Clark G.M., Elledge R., Fuqua S.A., Brown R.W., Chamness G.C., Osborne C.K., McGuire W.L. Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node-negative breast cancer. J. Natl. Cancer Inst. 1993, 85:200-206.
2. American Cancer Society, 2010. Cancer Facts & Figures 2010. In.
3. Atanaskova N., Keshamouni V.G., Krueger J.S., Schwartz J.A., Miller F., Reddy K.B. MAP kinase/estrogen receptor cross-talk enhances estrogen-mediated signaling and tumor growth but does not confer tamoxifen resistance. Oncogene 2002, 21:4000-4008.
4. Atsriku C., Britton D.J., Held J.M., Schilling B., Scott G.K., Gibson B.W., Benz C.C., Baldwin M.A. Systematic mapping of posttranslational modifications in human estrogen receptor-alpha with emphasis on novel phosphorylation sites. Mol. Cell Proteomics 2009, 8:467-480.
5. Beatson G.T. On the treatment of inoperable cases of carcinoma of the mamma: suggestions for a new method of treatment, with illustrative cases. Lancet 1896, 2:104-107.
6. Chan Q.K., Lam H.M., Ng C.F., Lee A.Y., Chan E.S., Ng H.K., Ho S.M., Lau K.M. Activation of GPR30 inhibits the growth of prostate cancer cells through sustained activation of ERK1/2, c-jun/c-fos-dependent upregulation of p21, and induction of G(2) cell-cycle arrest. Cell Death. Differ. 2010, 17:1511-1523.
7. Cheng J., Lee E.J., Madison L.D., Lazennec G. Expression of estrogen receptor beta in prostate carcinoma cells inhibits invasion and proliferation and triggers apoptosis. FEBS Lett. 2004, 566:169-172.
8. Driggers P.H., Segars J.H., Rubino D.M. The proto-oncoprotein Brx activates estrogen receptor beta by a p38 mitogen-activated protein kinase pathway. J. Biol. Chem. 2001, 276:46792-46797.
9. Faus H., Haendler B. Post-translational modifications of steroid receptors. Biomed. Pharmacother. 2006, 60:520-528.
10. Frigo D.E., Basu A., Nierth-Simpson E.N., Weldon C.B., Dugan C.M., Elliott S., Collins-Burow B.M., Salvo V.A., Zhu Y., Melnik L.I., Lopez G.N., Kushner P.J., Curiel T.J., Rowan B.G., McLachlan J.A., Burow M.E. P38 mitogen-activated protein kinase stimulates estrogen-mediated transcription and proliferation through the phosphorylation and potentiation of the p160 coactivator glucocorticoid receptor-interacting protein 1. Mol. Endocrinol. 2006, 20:971-983.
11. Gaben A.M., Saucier C., Bedin M., Redeuilh G., Mester J. Mitogenic activity of estrogens in human breast cancer cells does not rely on direct induction of mitogen-activated protein kinase/extracellularly regulated kinase or phosphatidylinositol 3-kinase. Mol. Endocrinol. 2004, 18:2700-2713.
12. Gburcik V., Picard D. The cell-specific activity of the estrogen receptor alpha may be fine-tuned by phosphorylation-induced structural gymnastics. Nucl. Recept. Signal. 2006, 4:e005.
13. Hamilton-Burke W., Coleman L., Cummings M., Green C.A., Holliday D.L., Horgan K., Maraqa L., Peter M.B., Pollock S., Shaaban A.M., Smith L., Speirs V. Phosphorylation of estrogen receptor beta at serine 105 is associated with good prognosis in breast cancer. Am. J. Pathol. 2010, 177:1079-1086.
14. Henson E.S., Gibson S.B. Surviving cell death through epidermal growth factor (EGF) signal transduction pathways: implications for cancer therapy. Cell Signal 2006, 18:2089-2097.
15. Hodges-Gallagher L., Valentine C.D., El B.S., Kushner P.J. Estrogen receptor beta increases the efficacy of antiestrogens by effects on apoptosis and cell cycling in breast cancer cells. Breast Cancer Res. Treat. 2008, 109:241-250.
16. Huang E.J., Wu C.C., Lee S.D., Chen J.H., Liu J.Y., Ko J.L., Lin J.A., Lu M.C., Chen L.M., Huang C.Y., Kuo W.W. Opposing action of estrogen receptors alpha and beta on tumor necrosis factor-alpha gene expression and caspase-8-mediated apoptotic effects in HA22T cells. Mol. Cell Biochem. 2006, 287:137-145.
17. Jorgensen C., Linding R. Directional and quantitative phosphorylation networks. Brief. Funct. Genomic. Proteomic. 2008, 7:17-26.
18. Kelly M.J., Levin E.R. Rapid actions of plasma membrane estrogen receptors. Trends Endocrinol. Metab 2001, 12:152-156.
19. Koehler K.F., Helguero L.A., Haldosen L.A., Warner M., Gustafsson J.A. Reflections on the discovery and significance of estrogen receptor beta. Endocr. Rev. 2005, 26:465-478.
20. Lam Y.W., Tam N.N., Evans J.E., Green K.M., Zhang X., Ho S.M. Differential proteomics in the aging Noble rat ventral prostate. Proteomics 2008, 8:2750-2763.
21. Lam Y.W., Yuan Y., Isaac J., Babu C.V., Meller J., Ho S.M. Comprehensive identification and modified-site mapping of S-nitrosylated targets in prostate epithelial cells. PLoS ONE 2010, 5:e9075.
22. Lamar C.A., Dorgan J.F., Longcope C., Stanczyk F.Z., Falk R.T., Stephenson H.E. Serum sex hormones and breast cancer risk factors in postmenopausal women. Cancer Epidemiol. Biomarkers Prev. 2003, 12:380-383.
23. Lannigan D.A. Estrogen receptor phosphorylation. Steroids 2003, 68:1-9.
24. Lazennec G., Bresson D., Lucas A., Chauveau C., Vignon F. ER beta inhibits proliferation and invasion of breast cancer cells. Endocrinology 2001, 142:4120-4130.
25. Le R.M., Poulard C., Cohen P., Sentis S., Renoir J.M., Corbo L. Cracking the estrogen receptor's posttranslational code in breast tumors. Endocr. Rev. 2011, 32:597-622.
26. Leav I., Lau K.M., Adams J.Y., McNeal J.E., Taplin M.E., Wang J., Singh H., Ho S.M. Comparative studies of the estrogen receptors beta and alpha and the androgen receptor in normal human prostate glands, dysplasia, and in primary and metastatic carcinoma. Am. J. Pathol. 2001, 159:79-92.
27. Leung Y.K., Lam H.M., Wu S., Song D., Levin L., Cheng L., Wu C.L., Ho S.M. Estrogen receptor beta2 and beta5 are associated with poor prognosis in prostate cancer, and promote cancer cell migration and invasion. Endocr. Relat. Cancer 2010, 17:675-689.
28. Leung Y.K., Mak P., Hassan S., Ho S.M. Estrogen receptor (ER)-beta isoforms: a key to understanding ER-beta signaling. Proc. Nat. Acad. Sci. U.S.A 2006, 103:13162-13167.
29. Leygue E., Dotzlaw H., Watson P.H., Murphy L.C. Altered estrogen receptor alpha and beta messenger RNA expression during human breast tumorigenesis. Cancer Res. 1998, 58:3197-3201.
30. Lindberg K., Strom A., Lock J.G., Gustafsson J.A., Haldosen L.A., Helguero L.A. Expression of estrogen receptor beta increases integrin alpha1 and integrin beta1 levels and enhances adhesion of breast cancer cells. J. Cell Physiol. 2010, 222:156-167.
31. Lu R., Serrero G. Mediation of estrogen mitogenic effect in human breast cancer MCF-7 cells by PC-cell-derived growth factor (PCDGF/granulin precursor). Proc. Nat. Acad. Sci. U.S.A 2001, 98:142-147.
32. Martineti V., Picariello L., Tognarini I., Carbonell S.S., Gozzini A., Azzari C., Mavilia C., Tanini A., Falchetti A., Fiorelli G., Tonelli F., Brandi M.L. ERbeta is a potent inhibitor of cell proliferation in the HCT8 human colon cancer cell line through regulation of cell cycle components. Endocr. Relat. Cancer 2005, 12:455-469.
33. Matthews J., Gustafsson J.A. Estrogen signaling: a subtle balance between ER alpha and ER beta. Mol. Interv. 2003, 3:281-292.
34. Mayya V., Han D.K. Phosphoproteomics by mass spectrometry: insights, implications, applications and limitations. Expert. Rev. Proteomics. 2009, 6:605-618.
35. Meriin A.B., Yaglom J.A., Gabai V.L., Zon L., Ganiatsas S., Mosser D.D., Zon L., Sherman M.Y. Protein-damaging stresses activate c-Jun N-terminal kinase via inhibition of its dephosphorylation: a novel pathway controlled by HSP72. Mol. Cell Biol. 1999, 19:2547-2555.
36. Murphy L.C., Skliris G.P., Rowan B.G., Al-Dhaheri M., Williams C., Penner C., Troup S., Begic S., Parisien M., Watson P.H. The relevance of phosphorylated forms of estrogen receptor in human breast cancer in vivo. J. Steroid Biochem. Mol. Biol. 2009, 114:90-95.
37. Murphy L.C., Weitsman G.E., Skliris G.P., Teh E.M., Li L., Peng B., Davie J.R., Ung K., Niu Y.L., Troup S., Tomes L., Watson P.H. Potential role of estrogen receptor alpha (ERalpha) phosphorylated at Serine118 in human breast cancer in vivo. J. Steroid Biochem. Mol. Biol. 2006, 102:139-146.
38. Paffenbarger R.S., Kampert J.B., Chang H.G. Characteristics that predict risk of breast cancer before and after the menopause. Am. J. Epidemiol. 1980, 112:258-268.
39. Pravettoni A., Mornati O., Martini P.G., Marino M., Colciago A., Celotti F., Motta M., Negri-Cesi P. Estrogen receptor beta (ERbeta) and inhibition of prostate cancer cell proliferation: studies on the possible mechanism of action in DU145 cells. Mol. Cell Endocrinol. 2007, 263:46-54.
40. Sauve K., Lepage J., Sanchez M., Heveker N., Tremblay A. Positive feedback activation of estrogen receptors by the CXCL12-CXCR4 pathway. Cancer Res. 2009, 69:5793-5800.
41. Shaaban A.M., Green A.R., Karthik S., Alizadeh Y., Hughes T.A., Harkins L., Ellis I.O., Robertson J.F., Paish E.C., Saunders P.T., Groome N.P., Speirs V. Nuclear and cytoplasmic expression of ERbeta1, ERbeta2, and ERbeta5 identifies distinct prognostic outcome for breast cancer patients. Clin. Cancer Res. 2008, 14:5228-5235.
42. Shaw J.A., Udokang K., Mosquera J.M., Chauhan H., Jones J.L., Walker R.A. Estrogen receptors alpha and beta differ in normal human breast and breast carcinomas. J. Pathol. 2002, 198:450-457.
43. Skliris G.P., Rowan B.G., Al-Dhaheri M., Williams C., Troup S., Begic S., Parisien M., Watson P.H., Murphy L.C. Immunohistochemical validation of multiple phospho-specific epitopes for estrogen receptor alpha (ERalpha) in tissue microarrays of ERalpha positive human breast carcinomas. Breast Cancer Res. Treat. 2009, 118:443-453.
44. St-Laurent V., Sanchez M., Charbonneau C., Tremblay A. Selective hormone-dependent repression of estrogen receptor beta by a p38-activated ErbB2/ErbB3 pathway. J. Steroid Biochem. Mol. Biol. 2005, 94:23-37.
45. Tharakan R., Lepont P., Singleton D., Kumar R., Khan S. Phosphorylation of estrogen receptor alpha, serine residue 305 enhances activity. Mol. Cell Endocrinol. 2008, 295:70-78.
46. Tremblay A., Giguere V. Contribution of steroid receptor coactivator-1 and CREB binding protein in ligand-independent activity of estrogen receptor beta. J. Steroid Biochem. Mol. Biol. 2001, 77:19-27.
47. Tremblay A., Tremblay G.B., Labrie F., Giguere V. Ligand-independent recruitment of SRC-1 to estrogen receptor beta through phosphorylation of activation function AF-1. Mol. Cell 1999, 3:513-519.
48. Tremblay G.B., Tremblay A., Copeland N.G., Gilbert D.J., Jenkins N.A., Labrie F., Giguere V. Cloning, chromosomal localization, and functional analysis of the murine estrogen receptor beta. Mol. Endocrinol. 1997, 11:353-365.
49. Warner M., Gustafsson J.A. The role of estrogen receptor beta (ERbeta) in malignant diseases - a new potential target for antiproliferative drugs in prevention and treatment of cancer. Biochem. Biophys. Res. Commun. 2010, 396:63-66.
50. Williams C., Edvardsson K., Lewandowski S.A., Strom A., Gustafsson J.A. A genome-wide study of the repressive effects of estrogen receptor beta on estrogen receptor alpha signaling in breast cancer cells. Oncogene 2008, 27:1019-1032.
51. Zhao C., Lam E.W., Sunters A., Enmark E., De Bella M.T., Coombes R.C., Gustafsson J.A., Dahlman-Wright K. Expression of estrogen receptor beta isoforms in normal breast epithelial cells and breast cancer: regulation by methylation. Oncogene 2003, 22:7600-7606.